INanoBio Inc. is a pioneering nanotechnology company based in Menlo Park, CA, specializing in the development of high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Their advanced technologies aim to extract systems scale information from complex disease biology, enabling the identification and detection of disease-specific molecular biomarkers at prodromal or pre-symptomatic stages, ultimately ushering in preemptive medicine in the future.
With a mission to revolutionize healthcare, INanoBio is focused on developing innovative tools and techniques that can detect diseases, such as cancer, in their early stages, leading to improved therapeutic outcomes and personalized treatment options. Their cutting-edge research includes the development of an advanced 3D nanopore transistor device for sequencing the whole human genome with high accuracy, at a fraction of the current cost and time. By leveraging CMOS semiconductor nanotechnology, INanoBio aims to make genome sequencing faster and more accessible, potentially enabling the sequencing of entire populations worldwide.
Generated from the website